Atropine Eye Drops for Myopia Control

Myopia is a growing public-health concern, particularly among children and adolescents. Low-dose atropine eye drops are used in some settings to slow axial elongation and myopia progression, but treatment decisions depend on age, refractive change, ocular findings, formulation, adherence, and clinician oversight. The evidence base supports a role for carefully selected patients, while also showing that concentration, duration, rebound after discontinuation, tolerability, and access remain important considerations.

Myopia management is shifting from correcting refractive error alone toward reducing progression risk through combined clinical assessment, behavioral measures, and interventions that may include low-dose atropine. Longer follow-up, standardized axial-length measurement, attention to treatment adherence, and individualized dosing are becoming more important. Regulatory approaches and prescribing practices differ across jurisdictions, creating variation in clinical pathways, formulation availability, informed consent, and monitoring requirements.

Artificial intelligence can support, but not replace, ophthalmic judgment in myopia management. Image-analysis systems may assist with retinal or optic-nerve documentation, while predictive models can help identify children at higher risk of rapid progression when trained on representative longitudinal data. Digital reminders and clinical decision-support tools may improve adherence and follow-up. However, validation across ethnicities and care settings, protection of pediatric data, explainability, cybersecurity, and prospective clinical evaluation are essential before AI outputs influence atropine prescribing.

Across North America, Europe, and Asia-Pacific, pediatric ophthalmology services increasingly emphasize early detection, axial-length monitoring, and evidence-based progression control, although access and regulatory status vary. Asia-Pacific remains especially important for myopia prevention and management because several countries report substantial childhood myopia burdens and have developed active school, family, and clinical responses. Latin America is balancing rising awareness with uneven specialist capacity and affordability. In the Middle East, urbanization, education patterns, and variable access to eye care shape demand for prevention and monitoring. Africa faces major screening, workforce, supply, and continuity-of-care constraints, making scalable referral and community-based models particularly relevant.

ASEAN members face differing regulatory systems, clinical resources, and urban-rural access, supporting the value of regionally adaptable protocols. BRICS countries combine large and diverse pediatric populations with varied ophthalmic capacity, manufacturing environments, and public-health priorities. The European Union benefits from shared regulatory structures but retains national differences in reimbursement and clinical practice. G7 health systems generally have stronger specialist infrastructure and research capacity, while still addressing affordability and service pressures. GCC countries often have comparatively concentrated specialist services and high urban access, alongside diverse expatriate populations. NATO members span multiple health systems, so defense cooperation itself does not imply uniform pediatric eye-care pathways or atropine access.

Australia and Japan have established ophthalmic research and clinical infrastructures, while China and South Korea are central to regional myopia-control activity and prevention efforts. India faces a large pediatric population alongside substantial differences between metropolitan and rural care. In the United States and Canada, prescribing, compounding, insurance coverage, and specialist access can vary by jurisdiction. European practice differs across France, Germany, Italy, Spain, and the United Kingdom because authorization, reimbursement, monitoring, and referral arrangements are not identical. Brazil and Mexico must address unequal access across public and private systems. Russia’s care environment is shaped by its own regulatory and service conditions, making local evidence and supply continuity important. Across all countries, pediatric examination quality, reliable formulations, informed consent, and follow-up are central to safe use.

Industry leaders should prioritize formulation quality, stability, age-appropriate packaging, and transparent evidence on concentration, tolerability, and rebound. Partnerships with ophthalmologists, schools, and primary-care providers can strengthen early identification and referral without replacing clinical diagnosis. Programs should define progression and axial-length outcomes, monitor adherence and adverse effects, and publish results across diverse populations. Access strategies should address affordability, supply reliability, language, and rural delivery. Digital and AI tools should undergo privacy, bias, usability, and clinical-validation review before deployment. Engagement with regulators and professional bodies can support consistent labeling, pharmacovigilance, and responsible education.

This executive summary is based on a structured review framework covering peer-reviewed clinical studies, systematic reviews, clinical guidance, regulatory information, and public-health evidence relevant to childhood myopia and atropine treatment. Analysis should distinguish randomized evidence from observational findings, document dose and follow-up differences, and assess outcomes such as spherical-equivalent progression, axial elongation, adverse effects, adherence, and rebound. Geographic comparisons consider regulatory context, service capacity, screening practices, and access rather than assuming that regional or country groupings are clinically homogeneous. Evidence quality, publication date, population characteristics, and applicability to local practice should be recorded transparently.

Low-dose atropine is an important option within a broader, individualized approach to childhood myopia control, but it is not a universal substitute for comprehensive eye care. Sustainable progress depends on early detection, appropriate patient selection, reliable formulations, clinician supervision, and consistent measurement of treatment response. Differences across regions, country groups, and national systems make adaptable implementation essential. Leaders who combine rigorous evidence generation with equitable access, responsible digital innovation, and long-term follow-up will be best positioned to improve outcomes for children at risk of progressive myopia.